Table 1.
Characteristics of the study population.
| Source | Country | Study Type | Study Period | Sample Size | Female | Male | Primary Cancer | Mean Age at Primary Diagnosis, Years | Follow-Up Duration, Years | SPTC ( + ) | SPTC (−) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Schlosser S [10] (2020) | Israel | R | 1991–2012 | 266 | 266 | 0 | Breast | 45.9 | 17 | 1 | 265 |
| Ciftciler R [21] (2019) | Turkey | R | 2001–2015 | 124 | 49 | 75 | MPN | 53.0 | 12 | 1 | 123 |
| Li S [32] (2019) | USA | R | 1992–2013 | 333,266 | 333,266 | 0 | Breast | 54.0 | N/A | 842 | 332,424 |
| Bryk S [42] (2018) | Finland | R | 1968–2013 | 986 | 986 | 0 | Ovarian | 40.0 | N/A | 6 | 980 |
| Kwon W [43] (2018) | Korea | R | 1993–2013 | 48,875 | 9524 | 39,351 | Bladder | 65.3 | 3.1 | 107 | 48,768 |
| Corso G [44] (2018) | Italy | R | 1994–2010 | 21,527 | 21,527 | 0 | Breast | N/A | N/A | 78 | 21,449 |
| Joung J [45] (2018) | Korea | R | 1993–2013 | 40,347 | 12,483 | 27,864 | RCC | 57.0 | 3.08 | 311 | 40,036 |
| Kumar V [46] (2018) | USA | R | 2002–2014 | 9200 | 3772 | 5428 | CML | N/A | 4.2 | 16 | 9184 |
| Chen T [47] (2017) | Germany/Sweden | R | 1997–2012 | 65,575 | 65,575 | 0 | Uterine | 68.5 | 3.9 | 42 | 65,533 |
| Sud A [11] (2017) | Sweden | R | 1965–2012 | 9522 | 4034 | 5488 | HL | 49.0 | 12.6 | 20 | 9502 |
| Kanninen T [12] (2017) | USA | R | 1992–2012 | 41,073 | 41,073 | 0 | Ovarian | 59.9 | N/A | 71 | 41,002 |
| Lococo F [13] (2017) | Italy | R | 1975–2011 | 3205 | 1069 | 2136 | Lung | 61.7 | N/A | 16 | 3189 |
| Liao Z [14] (2017) | USA | R | 1980–2011 | 1507 | 1507 | 0 | Germ Cell | 33.0 | 14.3 | 6 | 1501 |
| Liu Y [15] (2017) | China | R | 2008–2015 | 28 | 28 | 0 | Breast | 44.5 | 10.8 | 5 | 23 |
| Murray K [16] (2016) | USA | P | 1989–2010 | 3066 | 1972 | 1094 | RCC | 60.9 | 2.7 | 12 | 3054 |
| Krilaviciute A [17] (2016) | Lithuania | R | 1998–2007 | 12,584 | 8074 | 4510 | BCC | N/A | 14 | 30 | 12,554 |
| Silverman B [18] (2016) | Israel | R | 1990–2006 | 46,090 | 46,090 | 0 | Breast | N/A | 8.3 | 155 | 45,935 |
| Marcheselli, R [19] (2015) | Italy | R | 1996–2007 | 1830 | 1830 | 0 | Breast | 64.0 | 6.3 | 11 | 1819 |
| An J [5] (2015) | Korea | R | 1970–2009 | 6833 | 6833 | 0 | Breast | 43.4 | 4.4 | 81 | 6752 |
| Michaelson E [20] (2014) | USA | R | 1969–2008 | 1981 | 912 | 1069 | HL | 27.0 | 20.3 | 28 | 1953 |
| Koivisto-Korander R [22] (2012) | Europe | R | 1943–2000 | 8606 | 8606 | 0 | Uterine | N/A | 6.6 | 12 | 8594 |
| Antonelli A [23] (2012) | Italy | R | 1983–2009 | 1673 | 622 | 1051 | RCC | 61.6 | 5.9 | 15 | 1658 |
| Tabuchi T [7] (2012) | Japan | R | 1985–2004 | 13,385 | 4194 | 9191 | Gastric | N/A | 3.9 | 31 | 13,354 |
| Yadav B [24] (2009) | India | R | 1985–1995 | 1084 | 1084 | 0 | Breast | N/A | 12 | 1 | 1083 |
| Lee K [25] (2008) | China | R | 1979–2003 | 53,783 | 53,783 | 0 | Breast | 50.3 | 5.41 | 45 | 53,738 |
| Kirova Y [26] (2008) | France | R | 1981–1997 | 16,705 | 16,705 | 0 | Breast | 56.2 | 10.5 | 20 | 16,685 |
| Mellemkjaer L [27] (2006) | Europe, Australia, Canada, Singapore | R | 1943–2000 | 525,527 | 525,527 | 0 | Breast | N/A | 7.2 | 552 | 524,975 |
| Sadetzki S [28] (2003) | Israel | R | 1960–1998 | 49,207 | 49,207 | 0 | Breast | N/A | 7.1 | 72 | 49,135 |
| Adjadj É [29] (2003) | France | R | 1954–1983 | 200 | 200 | 0 | Breast | 48.0 | 9 | 8 | 192 |
| Tanaka H [30] (2001) | Japan | R | 1970–1995 | 2786 | 2786 | 0 | Breast | 50.9 | 8.6 | 7 | 2779 |
| Huang J [31] (2001) | USA | R | 1973–1993 | 194,798 | 194,798 | 0 | Breast | N/A | N/A | 140 | 194,658 |
| Li C [33] (2000) | USA | R | 1974–1994 | 2189 | 2189 | 0 | Breast | 59.8 | 4.2 | 20 | 2169 |
| Friedman, G [34] (2000) | USA | R | 1974–1997 | 3164 | 1516 | 1648 | BCC | N/A | 11.3 | 4 | 3160 |
| McCredie M [35] (1997) | Australia | R | 1972–1991 | 64,818 | 31,661 | 33,157 | Colorectal | 66.6 | 3.8 | 16 | 64,802 |
| Volk N [36] (1997) | Slovenia | R | 1961–1994 | 8791 | 8791 | 0 | Breast | 57.0 | 7.3 | 10 | 8781 |
| Lindelöf B [37] (1991) | Sweden | R | 1973–1983 | 1973 | 1039 | 934 | BCC | 68.0 | 6.5 | 5 | 1968 |
| Gutman M [38] (1991) | Israel | R | 1974–1986 | 370 | 237 | 133 | MM | 49.0 | 3.4 | 2 | 368 |
| Boice J [39] (1988) | USA, Denmark, Sweden, UK | R | N/A | 11,068 | 11,068 | 0 | Cervical | 52.0 | N/A | 43 | 11,025 |
| Murakami R [40] (1987) | Japan | P | 1965–1982 | 2786 | 2786 | 0 | Breast | 50.9 | 8.6 | 7 | 2779 |
| Ron E [41] (1984) | USA | R | 1935–1978 | 3147 | 3147 | 0 | Breast | 58.4 | N/A | 24 | 3123 |
R: Retrospective study, P: Prospective, SPTC: Second primary thyroid cancer, N/A: not applicable; MPN: Myeloproliferative neoplasms; CML: Chronic myelogenous leukemia; Lung: includes bronchopulmonary carcinoid HL: Hodgkin’s lymphoma; BCC: Basal cell carcinoma; MM: Malignant melanoma; RCC: Renal cell cancer.